Basophil activation test to BNT162b2 lacks specificity for predicting allergic reactions to the mRNA vaccine.

ABSTRACT:

Background

Allergic reactions to the coronavirus 2019 disease (COVID-19) mRNA vaccine (BNT162b2) were originally reported at higher rates than expected, contributing to vaccine hesitancy and, in some cases, unnecessary vaccine avoidance. Identification of a test that accurately predicts allergic reactions to mRNA vaccines is critical to improve patient care, particularly given the growing use of mRNA-based technologies.

Objective

We sought to determine the value of basophil activation tests (BATs) in predicting allergic reactions to the BNT162b2 vaccine.

Methods

Blood from 16 participants enrolled in the clinical trial COVID Vaccine Allergy Reaction (COVAAR [ClinicalTrials.gov identifier NCT04977479]) who reported a systemic allergic reaction to their first dose of th

SUBMITTER: Kee SA 

PROVIDER: S-EPMC12151657 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature